DD283771A5 - Verfahren zur herstellung einer peroralen praeparation einer saeure-instabilen verbindung - Google Patents

Verfahren zur herstellung einer peroralen praeparation einer saeure-instabilen verbindung Download PDF

Info

Publication number: DD283771A5
Authority: DD; German Democratic Republic
Prior art keywords: acid; compound; prepared; layer; tablets
Prior art date: 1988-05-18

Application number

DD89328639A

Other languages

German (de)

English (en)

Inventor

Yasuharu Saeki

Noritoshi Koyama

Sumio Watanabe

Shigeru Aoki

Original Assignee

��@�K�K�Kk��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-05-18

Filing date

1989-05-16

Publication date

1990-10-24

1989-05-16 Application filed by ��@�K�K�Kk�� filed Critical ��@�K�K�Kk��

1990-10-24 Publication of DD283771A5 publication Critical patent/DD283771A5/de

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 30
238000004519 manufacturing process Methods 0.000 title abstract description 3
239000000463 material Substances 0.000 claims abstract description 34
238000002360 preparation method Methods 0.000 claims abstract description 12
238000000576 coating method Methods 0.000 claims abstract description 10
239000011248 coating agent Substances 0.000 claims abstract description 9
239000010419 fine particle Substances 0.000 claims abstract description 4
238000000034 method Methods 0.000 claims description 16
-1 Magneiumcarbonat Chemical compound 0.000 claims description 13
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 12
235000014113 dietary fatty acids Nutrition 0.000 claims description 9
239000000194 fatty acid Substances 0.000 claims description 9
229930195729 fatty acid Natural products 0.000 claims description 9
239000001856 Ethyl cellulose Substances 0.000 claims description 8
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
229920001249 ethyl cellulose Polymers 0.000 claims description 8
235000019325 ethyl cellulose Nutrition 0.000 claims description 8
150000001556 benzimidazoles Chemical class 0.000 claims description 6
239000000395 magnesium oxide Substances 0.000 claims description 6
CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 6
235000019359 magnesium stearate Nutrition 0.000 claims description 6
AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 6
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 5
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
159000000000 sodium salts Chemical class 0.000 claims description 4
229930006000 Sucrose Natural products 0.000 claims description 3
239000000378 calcium silicate Substances 0.000 claims description 3
229910052918 calcium silicate Inorganic materials 0.000 claims description 3
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
239000008116 calcium stearate Substances 0.000 claims description 3
235000013539 calcium stearate Nutrition 0.000 claims description 3
OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 claims description 3
229920002689 polyvinyl acetate Polymers 0.000 claims description 3
239000011118 polyvinyl acetate Substances 0.000 claims description 3
YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims description 3
239000005720 sucrose Substances 0.000 claims description 3
229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 2
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
229940081734 cellulose acetate phthalate Drugs 0.000 claims description 2
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
239000000347 magnesium hydroxide Substances 0.000 claims description 2
229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
239000004014 plasticizer Substances 0.000 claims description 2
239000000725 suspension Substances 0.000 claims description 2
229920003145 methacrylic acid copolymer Polymers 0.000 claims 1
229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 1
235000012239 silicon dioxide Nutrition 0.000 claims 1
239000002253 acid Substances 0.000 abstract description 2
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
239000004744 fabric Substances 0.000 abstract 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
239000003826 tablet Substances 0.000 description 43
239000010410 layer Substances 0.000 description 24
239000000203 mixture Substances 0.000 description 22
239000000243 solution Substances 0.000 description 21
238000005303 weighing Methods 0.000 description 17
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 16
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
239000000454 talc Substances 0.000 description 12
235000012222 talc Nutrition 0.000 description 12
229910052623 talc Inorganic materials 0.000 description 12
239000002702 enteric coating Substances 0.000 description 9
238000009505 enteric coating Methods 0.000 description 9
239000004408 titanium dioxide Substances 0.000 description 8
230000000052 comparative effect Effects 0.000 description 7
239000006185 dispersion Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
239000012530 fluid Substances 0.000 description 6
239000008187 granular material Substances 0.000 description 6
239000001863 hydroxypropyl cellulose Substances 0.000 description 6
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
230000002378 acidificating effect Effects 0.000 description 5
229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
239000008112 carboxymethyl-cellulose Substances 0.000 description 4
230000015556 catabolic process Effects 0.000 description 4
241001233037 catfish Species 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
239000008120 corn starch Substances 0.000 description 4
229940099112 cornstarch Drugs 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
239000011229 interlayer Substances 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000007107 Stomach Ulcer Diseases 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
210000004211 gastric acid Anatomy 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
239000001095 magnesium carbonate Substances 0.000 description 2
229910000021 magnesium carbonate Inorganic materials 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
238000005266 casting Methods 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000007942 layered tablet Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Detergent Compositions (AREA)

DD89328639A 1988-05-18 1989-05-16 Verfahren zur herstellung einer peroralen praeparation einer saeure-instabilen verbindung DD283771A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP63121233A JPH0768125B2 (ja)	1988-05-18	1988-05-18	酸不安定化合物の内服用製剤

Publications (1)

Publication Number	Publication Date
DD283771A5 true DD283771A5 (de)	1990-10-24

Family

ID=14806208

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD89328639A DD283771A5 (de)	1988-05-18	1989-05-16	Verfahren zur herstellung einer peroralen praeparation einer saeure-instabilen verbindung

Country Status (14)

Country	Link
US (1)	US5035899A (da)
EP (1)	EP0342522B1 (da)
JP (1)	JPH0768125B2 (da)
KR (1)	KR910002641B1 (da)
AT (1)	ATE70442T1 (da)
CA (1)	CA1336958C (da)
DD (1)	DD283771A5 (da)
DE (1)	DE68900566D1 (da)
DK (1)	DK174664B1 (da)
ES (1)	ES2051919T3 (da)
FI (1)	FI93422C (da)
GR (1)	GR3003389T3 (da)
HU (1)	HU203200B (da)
NO (1)	NO178135C (da)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1246382B (it) *	1990-04-17	1994-11-18	Eurand Int	Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
YU48263B (sh) *	1991-06-17	1997-09-30	Byk Gulden Lomberg Chemische Fabrik Gmbh.	Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US6764697B1 (en) *	1991-06-27	2004-07-20	Alza Corporation	System for delaying drug delivery up to seven hours
PT571973E (pt) *	1992-05-29	2000-05-31	Nikken Chemicals Co Ltd	Comprimidos de valproato de sodio de libertacao retardada
SE9302395D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	New pharmaceutical formulation
CA2193681A1 (en) *	1994-07-08	1996-01-25	Astra Aktiebolag	New oral pharmaceutical formulation containing magnesium salt of omeprazole
ES2094694B1 (es) *	1995-02-01	1997-12-16	Esteve Quimica Sa	Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) *	1995-02-09	1995-02-09	Astra Ab	New pharmaceutical formulation and process
US5945124A (en) *	1995-07-05	1999-08-31	Byk Gulden Chemische Fabrik Gmbh	Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE512835C2 (sv) *	1996-01-08	2000-05-22	Astrazeneca Ab	Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
JPH09323926A (ja) *	1996-03-15	1997-12-16	Nikken Chem Co Ltd	バルプロ酸ナトリウムの徐放性錠剤
US5788987A (en) *	1997-01-29	1998-08-04	Poli Industria Chimica Spa	Methods for treating early morning pathologies
US5891474A (en)	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
GB9710800D0 (en) *	1997-05-23	1997-07-23	Cipla Limited	Pharmaceutical composition and method of preparing it
US6296876B1 (en)	1997-10-06	2001-10-02	Isa Odidi	Pharmaceutical formulations for acid labile substances
FR2774288B1 (fr) *	1998-01-30	2001-09-07	Ethypharm Sa	Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
CA2330324A1 (en) *	1998-04-30	1999-11-04	Sepracor Inc.	S-rabeprazole compositions and methods
US6174902B1 (en)	1999-04-28	2001-01-16	Sepracor Inc.	R-rabeprazole compositions and methods
FR2793688B1 (fr)	1999-05-21	2003-06-13	Ethypharm Lab Prod Ethiques	Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
JP4980527B2 (ja)	1999-06-07	2012-07-18	ニコメッドゲゼルシャフトミットベシュレンクテルハフツング	酸に不安定な活性化合物を含有する新規の製剤および投与形
US6245913B1 (en)	1999-06-30	2001-06-12	Wockhardt Europe Limited	Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ES2168043B1 (es) *	1999-09-13	2003-04-01	Esteve Labor Dr	Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
DE19959419A1 (de)	1999-12-09	2001-06-21	Ratiopharm Gmbh	Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
AU2001296908A1 (en) *	2000-09-29	2002-04-08	Geneva Pharmaceuticals, Inc.	Proton pump inhibitor formulation
JP2002234842A (ja) *	2001-02-09	2002-08-23	Kyowa Yakuhin Kogyo Kk	内服腸溶性製剤
EA008224B1 (ru) *	2001-03-13	2007-04-27	Пенвест Фармасьютикалз Ко.	Хронотерапевтические дозированные формы
US8206741B2 (en)	2001-06-01	2012-06-26	Pozen Inc.	Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20050163846A1 (en) *	2001-11-21	2005-07-28	Eisai Co., Ltd.	Preparation composition containing acid-unstable physiologically active compound, and process for producing same
DE10211289A1 (de)	2002-03-14	2003-09-25	Basf Ag	Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität
US20030228363A1 (en) *	2002-06-07	2003-12-11	Patel Mahendra R.	Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040028737A1 (en) *	2002-08-12	2004-02-12	Kopran Research Laboratories Limited	Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US20040146558A1 (en) *	2003-01-28	2004-07-29	Kyowa Pharmaceutical Co., Ltd.	Oral enteric-coated preparation
JP2004231520A (ja) *	2003-01-28	2004-08-19	Nichiko Pharmaceutical Co Ltd	保存安定性及び溶出速度に優れた医薬組成物
CL2004000983A1 (es)	2003-05-08	2005-03-04	Altana Pharma Ag	Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es)	2003-05-08	2005-03-22	Altana Pharma Ag	Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
EP2112920B1 (en)	2003-06-26	2018-07-25	Intellipharmaceutics Corp.	Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US20050147663A1 (en) *	2003-07-17	2005-07-07	Mohan Mailatur S.	Method of treatment for improved bioavailability
US20050042277A1 (en) *	2003-07-17	2005-02-24	Irukulla Srinivas	Pharmaceutical compositions having a swellable coating
CA2538929A1 (en) *	2003-09-11	2005-03-24	Glykon Technologies Group, Llc	Enteric delivery of (-)-hydroxycitric acid
US20050118267A1 (en) *	2003-09-19	2005-06-02	Penwest Pharmaceuticals Co.	Chronotherapeutic dosage forms
EA200600598A1 (ru) *	2003-09-19	2006-08-25	Пенвест Фармасьютикалз Ко.	Лекарственные формы замедленного высвобождения
US20070292498A1 (en) *	2003-11-05	2007-12-20	Warren Hall	Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005051362A2 (en) *	2003-11-28	2005-06-09	Ranbaxy Laboratories Limited	Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating
EP1699458A4 (en) *	2003-12-30	2012-04-25	Reddys Lab Ltd Dr	PHARMACEUTICAL COMPOSITION
NZ549838A (en) *	2004-03-26	2010-04-30	Eisai R&D Man Co Ltd	Coated controlled-release preparation containing a gastric acid secretion inhibitor
US20050239845A1 (en) *	2004-04-16	2005-10-27	Santarus, Inc.	Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8394409B2 (en)	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
US20060024362A1 (en) *	2004-07-29	2006-02-02	Pawan Seth	Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en)	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
US20060280789A1 (en) *	2004-12-27	2006-12-14	Eisai Research Institute	Sustained release formulations
US20060246003A1 (en) *	2004-12-27	2006-11-02	Eisai Co. Ltd.	Composition containing anti-dementia drug
US20070129402A1 (en) *	2004-12-27	2007-06-07	Eisai Research Institute	Sustained release formulations
US20060160852A1 (en) *	2004-12-27	2006-07-20	Eisai Co. Ltd.	Composition containing anti-dementia drug
US8481565B2 (en) *	2004-12-27	2013-07-09	Eisai R&D Management Co., Ltd.	Method for stabilizing anti-dementia drug
WO2006085335A2 (en) *	2005-01-03	2006-08-17	Lupin Limited	Pharmaceutical composition of acid labile substances
WO2007005380A2 (en) *	2005-06-29	2007-01-11	Analog Devices, Inc.	Improved charge/discharge control circuit for audio device
US20090148519A1 (en) *	2005-09-29	2009-06-11	Yasuhiro Zaima	Pulsed-release preparation having improved disintegration properties in vivo
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1973532A1 (en) *	2006-01-16	2008-10-01	Jubilant Organosys Limited	Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
CA2665226C (en)	2006-10-05	2014-05-13	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
WO2008062320A2 (en) *	2006-10-06	2008-05-29	Eisai R&D Management Co., Ltd	Extended release formulations of a proton pump inhibitor
AU2007317561A1 (en)	2006-10-27	2008-05-15	The Curators Of The University Of Missouri	Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
JPWO2009069280A1 (ja)	2007-11-27	2011-04-07	大原薬品工業株式会社	造粒物の製造法
SI22806A (sl) *	2008-06-23	2009-12-31	Krka, Tovarna Zdravil, D.D., Novo Mesto	Nove kristalinične oblike natrijevega rabeprazola
CH699302B1 (de) *	2008-08-11	2012-03-15	Mepha Gmbh	Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
EA201100313A1 (ru)	2008-09-09	2011-10-31	Астразенека Аб	Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
US20100093747A1 (en) *	2008-10-10	2010-04-15	Erica Brook Goodhew	Method of inducing negative chemotaxis
US20110008432A1 (en) *	2009-06-25	2011-01-13	Pozen Inc.	Method for Treating a Patient in Need of Aspirin Therapy
CA2764963C (en)	2009-06-25	2016-11-01	Astrazeneca Ab	Method for treating a patient at risk for developing an nsaid-associated ulcer
CA2778748A1 (en) *	2011-06-01	2012-12-01	Nitto Denko Corporation	Particulate preparation and method for producing the same
KR20140113667A (ko)	2011-12-16	2014-09-24	아토픽스 테라퓨릭스 리미티드	호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
BR112014016085A8 (pt)	2011-12-28	2017-07-04	Pozen Inc	composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
AU2014223658B2 (en) *	2013-03-01	2018-10-18	Bpsi Holdings, Llc.	Delayed release film coatings containing calcium silicate and substrates coated therewith
JP6344678B2 (ja) *	2013-09-27	2018-06-20	キョーリンリメディオ株式会社	テルミサルタン含有製剤及びその製造方法
WO2024075017A1 (en)	2022-10-04	2024-04-11	Zabirnyk Arsenii	Inhibition of aortic valve calcification

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
GB2189699A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
FI90544C (fi) *	1986-11-13	1994-02-25	Eisai Co Ltd	Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi

1988
- 1988-05-18 JP JP63121233A patent/JPH0768125B2/ja not_active Expired - Lifetime
1989
- 1989-04-04 US US07/332,731 patent/US5035899A/en not_active Expired - Lifetime
- 1989-04-06 FI FI891650A patent/FI93422C/fi not_active IP Right Cessation
- 1989-04-18 KR KR1019890005092A patent/KR910002641B1/ko not_active Expired
- 1989-05-02 CA CA000598474A patent/CA1336958C/en not_active Expired - Lifetime
- 1989-05-11 DE DE8989108492T patent/DE68900566D1/de not_active Expired - Lifetime
- 1989-05-11 AT AT89108492T patent/ATE70442T1/de not_active IP Right Cessation
- 1989-05-11 ES ES89108492T patent/ES2051919T3/es not_active Expired - Lifetime
- 1989-05-11 EP EP89108492A patent/EP0342522B1/en not_active Expired - Lifetime
- 1989-05-12 NO NO891935A patent/NO178135C/no not_active IP Right Cessation
- 1989-05-16 DD DD89328639A patent/DD283771A5/de unknown
- 1989-05-17 DK DK198902391A patent/DK174664B1/da not_active IP Right Cessation
- 1989-05-17 HU HU892461A patent/HU203200B/hu unknown
1991
- 1991-12-19 GR GR91401411T patent/GR3003389T3/el unknown

Also Published As

Publication number	Publication date
JPH0768125B2 (ja)	1995-07-26
NO178135C (no)	1996-01-31
NO891935L (no)	1989-11-20
DK239189D0 (da)	1989-05-17
HU203200B (en)	1991-06-28
ES2051919T3 (es)	1994-07-01
GR3003389T3 (en)	1993-02-17
NO178135B (no)	1995-10-23
HUT51896A (en)	1990-06-28
EP0342522A1 (en)	1989-11-23
DK174664B1 (da)	2003-08-18
NO891935D0 (no)	1989-05-12
FI891650A0 (fi)	1989-04-06
CA1336958C (en)	1995-09-12
KR890016964A (ko)	1989-12-14
DE68900566D1 (de)	1992-01-30
FI93422B (fi)	1994-12-30
FI891650L (fi)	1989-11-19
EP0342522B1 (en)	1991-12-18
FI93422C (fi)	1995-04-10
JPH01290628A (ja)	1989-11-22
US5035899A (en)	1991-07-30
DK239189A (da)	1989-11-19
KR910002641B1 (ko)	1991-04-27
ATE70442T1 (de)	1992-01-15

Legal Events

Date	Code	Title	Description
2004-04-28	IF04	In force in the year 2004	Expiry date: 20090517

Publication	Publication Date	Title
DE69631834T2 (de)	2005-02-10	Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
DE69102211T3 (de)	1997-08-28	Pharmazeutische Zubereitung mit kontrollierter Freigabe.
DE69020758T2 (de)	1995-12-07	Die Wirkstoffabgabe steuerndes Überzugsmaterial für lang wirksame Formulierungen.
DE69721845T2 (de)	2004-02-19	Orale morphinzubereitung in teilchenform
US5035899A (en)	1991-07-30	Peroral preparation of acid-unstable compound
DE69230112T2 (de)	2000-03-02	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EP0078430B2 (de)	1993-02-10	Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
DE3915150C2 (de)	1997-04-17	Lang-wirkendes Diclofenac-Natrium-Präparat
DE3688532T2 (de)	1993-09-23	Pharmazeutische darreichungsform mit verzoegerter abgabe.
DE3751851T2 (de)	1996-10-31	Verwendung von spezifischem Kernmaterial und Schichten zur Herstellung pharmazeutischer Formulierungen, die stabil gegen die Verfärbung säurelabiler Verbindungen sind
DE60100186T2 (de)	2004-01-08	Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
DE69833490T2 (de)	2006-10-19	Orale pharmazeutische zusammensetzung enthaltend ein benzimidazolderivat mit antiulcus wirkung und verfahren zu seiner herstellung
DE60029712T2 (de)	2007-08-02	Feste oral anzuwendende Arzneizubereitung mit gesteuerter Wirkstoffabgabe enthaltend eine säureempfindliche Benzimidazolverbindung
DE3024858A1 (de)	1981-01-22	Anhaltend freigebende pharmazeutische zubereitung eines festen medikamentmaterials
DE60038447T2 (de)	2009-04-16	Stabile benzimidazol zusammensetzungen
DE68908297T2 (de)	1994-03-31	Formgepresste Zusammensetzungen.
DE10209982A1 (de)	2003-09-25	Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
DE60036014T2 (de)	2008-04-30	Methode zur stabilisierung von benzimidazol-verbindungen
EP1485094A1 (de)	2004-12-15	ORAL ZU APPLIZIERENDE DARREICHUNGSFORM FÜR 3- (2-&lcub;4-(HEXYLOXYCARBONYLAMINO-IMINO-METHYL)-PHENYLAMINO -METHYL&rcub;-1-METHYL-1 i H /i -BENZIMIDAZOL-5-CARBONYL)-PYRIDIN-2-YL-AMINO -PROPIONSÄURE-ETHYLESTER UND DESSEN SALZE
DE69916876T2 (de)	2005-03-31	Umhüllte teilchen bestehend aus kristallisiertem granuliertem ibuprofen
DE102008046650A1 (de)	2010-03-11	Quetiapin enthaltende Retardtablette
DE69706969T2 (de)	2002-04-25	Metall valproat-tabletten mit verzoegerter freisetzung
DE60114887T2 (de)	2006-07-20	Partikuläre zusammensetzung mit sigmoidem freisetzungsmuster enthaltend eletriptan hydrobromid
DE60035579T2 (de)	2008-04-17	Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
DE3419128A1 (de)	1985-11-28	Dihydropyridinpraeparate und verfahren zu ihrer herstellung